Achieve Life Sciences (ACHV) Total Current Liabilities (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Total Current Liabilities came in at $11.8 million in Q1 2026, up 65.96% YoY from $7.1 million in Q1 2025, and up 30.29% on a QoQ basis from $9.1 million in Q4 2025.
Achieve Life Sciences (ACHV) Total Current Liabilities (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Total Current Liabilities data on file, last reported at $11.8 million in Q1 2026.
- Quarterly Total Current Liabilities rose 65.96% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.8 million (up 65.96% YoY) and the FY2025 annual result came in at $9.1 million, up 35.92% from the prior year.
- Total Current Liabilities climbed to $11.8 million in Q1 2026, from $9.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $21.6 million in Q4 2022 to a low of $3.4 million in Q2 2023.
- A 5-year average of $10.6 million and a median of $8.6 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities soared 406.26% — and 2024, when it sank 67.9%.
- Tracing ACHV's Total Current Liabilities over 5 years: stood at $21.6 million in 2022, then fell by 3.64% to $20.8 million in 2023, then slumped by 67.9% to $6.7 million in 2024, then surged by 35.92% to $9.1 million in 2025, then surged by 30.29% to $11.8 million in 2026.
- The last three Total Current Liabilities figures came in at $11.8 million (Q1 2026), $9.1 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 197.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 197.66 Mn |
| Mar 31, 2026 | 11.83 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 9.73 Mn |
| Jun 30, 2025 | 8.57 Mn |
| Mar 31, 2025 | 7.13 Mn |
| Dec 31, 2024 | 6.68 Mn |
| Sep 30, 2024 | 6.72 Mn |
| Jun 30, 2024 | 13.70 Mn |
| Mar 31, 2024 | 20.57 Mn |
| Dec 31, 2023 | 20.81 Mn |
| Sep 30, 2023 | 4.08 Mn |
| Jun 30, 2023 | 3.45 Mn |
| Mar 31, 2023 | 20.30 Mn |
| Dec 31, 2022 | 21.60 Mn |
| Sep 30, 2022 | 6.92 Mn |
| Jun 30, 2022 | 5.36 Mn |
| Mar 31, 2022 | 4.01 Mn |
| Dec 31, 2021 | 4.55 Mn |
| Sep 30, 2021 | 3.08 Mn |